Market Insights: Growth in Autoimmune Hepatitis Diagnosis and Treatment
The market for autoimmune hepatitis diagnosis and treatment is projected to expand significantly, increasing from an estimated USD 14.03 billion in 2023 to over USD 19.15 billion by 2032. This growth reflects a steady compound annual growth rate (CAGR) of 3.3% during the forecast period, driven by rising demand for innovative treatment solutions and improved access to healthcare services globally.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5124
Recent Developments
- In January 2022, the U.S. Food and Drug Administration (FDA) granted approval to Lupin’s Tenofovir alafenamide tablets for the treatment of chronic hepatitis B viral infection, offering a new treatment option for patients battling this condition.
- In June 2022, Echosens partnered with Novo Nordisk to improve accessibility to non-invasive tests for diagnosing Non-Alcoholic Steatohepatitis (NASH), a liver condition. Their collaboration aims to expand NASH diagnoses, particularly for those with severe cases, and increase the number of diagnoses by four times by 2025.